Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-4578 plus nivolumab, mFOLFOX6, and bevacizumab versus standard of care in first-line PD-L1-positive advanced colorectal cancer
2024-519590-19-00Phase 2Authorised
- Sponsor
- Ono Pharmaceutical
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, open-label trial of ONO-4578 in colorectal cancer (CRC) (3 arms), sponsored by Ono Pharmaceutical. Primary endpoints: Safety and tolerability and Overall response rate by blinded independent central review. Planned start Nov 2025; status: authorised.
02
Drugs
ONO-4578
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2024-519590-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519590-19-00.